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VIROLOGY
Short Communication:
Analysis of Minor Populations of Human Immunodeficiency
Virus by Primer Identification and Insertion-Deletion
and Carry Forward Correction Pipelines
Paul Hughes,1 Wenjie Deng,2 Scott C. Olson,1,3 Robert W. Coombs,4,5
Michael H. Chung,4,5 and Lisa M. Frenkel1,3,4,6
Abstract
Accurate analysis of minor populations of drug-resistant HIV requires analysis of a sufficient number of viral
templates. We assessed the effect of experimental conditions on the analysis of HIV pol 454 pyrosequences
generated from plasma using (1) the ‘‘Insertion-deletion (indel) and Carry Forward Correction’’ (ICC) pipeline,
which clusters sequence reads using a nonsubstitution approach and can correct for indels and carry forward
errors, and (2) the ‘‘Primer Identification (ID)’’ method, which facilitates construction of a consensus sequence
to correct for sequencing errors and allelic skewing. The Primer ID and ICC methods produced similar
estimates of viral diversity, but differed in the number of sequence variants generated. Sequence preparation for
ICC was comparably simple, but was limited by an inability to assess the number of templates analyzed and
allelic skewing. The more costly Primer ID method corrected for allelic skewing and provided the number of
viral templates analyzed, which revealed that amplifiable HIV templates varied across specimens and did not
correlate with clinical viral load. This latter observation highlights the value of the Primer ID method, which by
determining the number of templates amplified, enables more accurate assessment of minority species in the
virus population, which may be relevant to prescribing effective antiretroviral therapy.
Human immunodeficiency virus type-1 (HIV) mu-tates due to the inability of its reverse transcriptase
enzyme to proofread.1–3 The in vivo mutation rate is esti-
mated at 3.4 · 10-5 mutations per nucleotide per replication
cycle. Thus, given a genome length of*104 base pairs (bp),
and production of 1010 new virions each day, the HIV pop-
ulation within an infected individual diversifies rapidly.1,4
Drug-resistant variants increase in prevalence under se-
lective drug pressure, but often regress when antiretrovirals
are suspended, due to a relatively poor replication capacity.
Multiple investigators have sought to determine if low levels
of drug-resistant variants in antiretroviral-naive individuals
are clinically significant,5–9 and whether their detection prior
to antiretroviral treatment (ART) should alter the choice of
antiretrovirals.8–11 For example, a study of antiretroviral-
naive individuals using 454-pyrosequencing found that low
levels of mutations conferring resistance to nonnucleoside
reverse transcriptase inhibitors (NNRTIs) had a significantly
greater risk of virologic failure with an NNRTI-based regi-
men compared to those without mutations.12
To confidently ascribe an attributable risk for virologic
failure to minority variants detected by multiple parallel se-
quencing (MPS) technologies, an adequate number of viral
templates must be sampled, with sufficient multiplicity of
reads per template. MPS studies of HIV often utilize the
clinical plasma viral load as a proxy for the number of tem-
plates assayed. However, clinical viral load tests target con-
served regions of the HIV genome to minimize the effects of
differential primer binding, amplify relatively short spans of
the viral template to maximize amplification efficiency, and
use internal controls to correct for inefficiencies in extraction
and amplification.13 MPS for drug resistance generally has
not utilized similar measures to optimize viral amplification.
Consequently, the clinical viral load may overrepresent the
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number of amplifiable templates in ‘‘second-generation deep
sequencing technologies,’’ including 454-pyrosequencing
(Roche), and the sequences generated may be biased by
primer sequences, length of amplicons, enzyme fidelity, and
PCR conditions.13,14
Sequence analysis pipelines can also affect the results of
MPS. The Insertion-deletion (indel) and Carry Forward
Correction (ICC) pipeline clusters sequence reads using a
nonsubstitution approach and corrects for indels and carry
forward errors.15 This pipeline, along with other conven-
tional pipelines, assumes equal amplification of viral tem-
plates and therefore that proportions of final reads accurately
reflect the diversity of an individual’s virus population.
Alternatively, the Primer ID method16 addresses in-
accuracies of estimating template input and corrects skewing
of allelic frequencies and PCR and sequencing errors by
constructing a consensus sequence for each template that
allows for quantification of template input.16–19 Each viral
template is labeled with a unique, randomly generated, 8-bp
identifier (i.e., the Primer ID) adjacent to the 5¢ end of the
gene-specific portion of the primer used to reverse transcribe
the viral RNA. The tagging of each template with a unique
Primer ID is carried throughout PCR and sequencing, and is
used to tabulate the number of viral templates amplified.
Three or more Primer ID reads are used to generate a con-
sensus sequence, which corrects PCR and sequencing errors.
In this study the Primer ID method was used to examine the
effect of viral load and read depth on the amplified products
fromHIV pol templates. Additionally, the Primer IDmethod16
was compared to ICC, to evaluate the correction of se-
quencing errors and differences in the genetic composition of
the final sequence output.
Blood plasma from 12 antiretroviral-naive individuals in-
fected with HIV subtype A from whom sufficient specimen
volume was available and plasma HIV RNA was >10K
copies/ml was randomly selected for this study and HIV RNA
was quantified by a real-time polymerase chain reaction as-
say (Abbott RealTime HIV-1, Abbott Global). Use of rem-
nant specimens for assay development was approved by the
University of Washington’s Institutional Review Board.
Nucleic acids extracted using silica20 from 800ll of each
plasma specimen were resuspended into a volume of 50ll.
Ten microliters of each RNA extract was reverse transcribed
(Blueprint 1st Strand cDNA Synthesis Kit, Takara Bio, Inc.)
and primers with ID tags (NNNNNNNN) were added as de-
scribed16 to reverse transcribe two regions of HIV pol: primer
2994R and primer 3267R (Table 1). The 3¢ end of both primers
anneal to the RT region of HIV pol (HXB2 2965) 2994,
HXB2 3243) 3267).16 Adjacent to the 5¢ end of the Primer
ID was a region complementary to primer sequences of a
subsequent heminested 2nd-round PCR.16 After cDNA syn-
thesis the solution was purified (High Pure PCR Template
Preparation Kit, Roche) to remove excess primers that could
potentially tag template in subsequent rounds of PCR.
The primer ID cDNA aliquots were amplified by nested
PCR using primers in Table 1 to produce two amplicons of
regions encoding HIV reverse transcriptase codons 34–138
(Amplicon 1) and 149–230 (Amplicon 2). Four identical first
round reactions, each with 5 ll cDNA, were performed for
each sample to avoid inhibition of PCR by adding excess
cDNA. Each reaction volume contained cDNA, 0.4 lM of
amplicon specific, forward and reverse primers, 2.5 units
FastStart High Fidelity Enzyme (Roche), 5 ll 10x FastStart
High Fidelity master mix with MgCl2 (Roche), 0.2mM
dNTPs, and dH2O to equal 50 ll. Five microliters of each first
round amplicon was pooled and 2 ll of each pool was am-
plified in the second round reaction. Second round reagents
were identical to that of first round, with 3 ll of dH2O to bring
the reaction volume to 50 ll. A unique 10-base multiplex
identifier (MID) was added to each subject’s amplicon during
a second round PCR to allow sequencing of multiple subjects
in one region of the pyrosequencing plate. The first round
conditions were 95C for 2min, 35 cycles of 95C for 30 s,
55C for 30 s, and 72C for 1min, and a final extension at
72C for 7min. The second round conditions were 95C for
2min, 30 cycles of 95C for 30 s, 60C for 20 s, and 72C for
45 s, and one final extension at 72C for 5min.
The pKS q23-17 DNA plasmid was used as a control21 for
PCR and pyrosequencing errors. The plasmid was amplified
with primers 2994R and 2571F in the first round and primers
2621F and ngs2R in the second round (Table 1) to create
Amplicon 1, and primers 3267R and 2933F in the first round
and primers 2965F and ngs2R in the second round to create
Amplicon 2.
Table 1. Primers Used for Amplification of HIV-1 Subtype A
Primer name Amplicon 1 Position in HXB2
cDNA synthesis (2994R) 5¢-GCCTTGCCAGCACGCTCAGGCCTTGCACGNNNNN
NNNTCACATTGTACTGATAYCTRAYWCCTGGTG-3¢
2965) 2994
1st round forward (2571F) GTACCAGTAAMATTAAAGCCAGGAATGG 2571/ 2598
1st round reverse (ngs1R) GCCTTGCCAGCACGCTCAGGC Not gene specific
2nd round forward (2621F) MID-GCCATTGACAGAAGARAAAATAAAAGC 2621/ 2647
2nd round reverse (ngs2R) MID-CCAGCACGCTCAGGCCTTGCA Not gene specific
Primer name Amplicon 2 Position in HXB2
cDNA synthesis (3267R) 5¢-GCCTTGCCAGCACGCTCAGGCCTTGCACGNNN
NNNNNTCCAYTTGTCAGGATGGAGYTCATA -3¢
3243) 3267
1st round forward (2932F) CTGCATTYACYATACCTAGTAYAAAC 2932/ 2957
1st round reverse (ngs1R) GCCTTGCCAGCACGCTCAGGC Not gene specific
2nd round forward (2965F) MID-CACCAGGWRTYAGRTATCAGTACAATGT 2965/ 2992
2nd round reverse (ngs2R) MID-CCAGCACGCTCAGGCCTTGCA Not gene specific
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After nested PCR, amplicons were purified (High Pure PCR
Template Preparation Kit, Roche). The amplicons from each
sample were quantified (Quant-iT PicoGreen dsDNA Assay
Kit, Invitrogen) and diluted with water to 109 copies/ll. An
equal volume of primer ID labeled Amplicon 1 and Amplicon
2 fragments from each sample was pooled and 2ll of the pool
was added to 198ll of nuclease free water to bring the
concentration to 107 copies/ll for pyrosequencing. One
subject’s sample (Subject 6) was sequenced in two separate
gaskets to assess reproducibility and the impact of doubling
the number of reads on the final sequence output.
Primer ID16 and ICC15 pipelines were used to analyze the
pyrosequencing dataset and generate final sequence variants.
The study comparisons included the following: (1) the number
of unique IDs generated by the Primer IDmethod compared to
copies input based on viral load; (2) the number of final se-
quence variants determined by the Primer ID method, per-
formed by condensing monotypic consensus sequences from
different primer IDs, vs. the ICC method15; (3) the HIV di-
versity of subjects’ final HIV sequence population from each
pipeline was compared using the DIVEIN web tool22; and (4)
the effect of doubling the number of 454-pyrosequencing reads
on the number of sequence variants by sequencing the same
two amplicons generated from one subject in one vs. two
gaskets of the 454-pyrosequencing plate.
A total of 99,696 sequence reads generated by 454-
pyrosequencing for the 14 amplicons passed criteria for full
length, PCR primer, primer ID, and MID; with two sequenced
twice, reads ranged from 4,676 to 11,693 per amplicon. More
truncated sequences were observed for Amplicon 1 (317 bp)
compared to Amplicon 2 (250bp) ( p= 0.028 Wilcoxon sign
rank test), most likely due to the greater length of region am-
plified. While all full-length reads were analyzed using the
ICC pipeline, only those with unique IDs ‡3 reads were ana-
lyzed using the Primer IDmethod, which variably affected the
number of reads by amplicon and specimen. The number of
reads per each unique primer ID was not uniform, but pro-
gressively diminished, as shown for Subject 4 (Fig. 1). Across
subjects and amplicons, 7% of reads were discarded due to
incomplete length and 61% due to <3 reads per Primer ID
(Supplementary Table S1; Supplementary Data are available
online at www.liebertpub.com/aid).
The input number ofHIV templates and the template length/
region amplified affected the yield of 454-prosequencing reads
using the Primer ID method. The yield of unique IDs (any
number of reads) was substantially less than the estimated
input based on clinical viral load across all samples (data not
shown), as was the number of unique IDs ‡3 (Fig. 2A). Re-
latively few unique IDs ‡3were observedwhen a low or a high
input of viral templates, as estimated by clinical viral load, was
assayed. The proportion of viral templates with Primer IDs ‡3
sequences generated by a set number of 454-pyrosequencing
reads diminished with increasing input of viral templates,
based on the clinical viral load assay (Fig. 2B). Increasing the
number of reads for a subject’s specimen, shown by combining
the sequence data from assaying Subject 6’s amplicons in two
different 454-plates, found that the number of raw reads in-
creased in an additive fashion and the number of unique IDs
with three or more reads also increased (Table 2). After
combining the Primer ID consensus sequences with identical
HIV pol sequences the number of final sequence variants in-
creased for Amplicon 1 but results for Amplicon 2 were varied
(Table 2).
To reduce sequencing expenses, some researchers may
choose to forgo the Primer ID method. A comparison of the
number of final sequence variants generated by Primer ID to
ICC using a Wilcoxon sign rank test at a 95% confidence
level found significantly more variants by Primer ID for
Amplicon 1 ( p = 0.028) and no significant difference for
Amplicon 2 ( p = 0.25).
To compare the genetic makeup of the populations gen-
erated by each method, phylogenetic analyses were per-
formed for each subject and diversity was calculated. Using a
Wilcoxon sign rank test at 95% confidence, the diversities
produced by each method were not significantly different
( p = 0.173 for Amplicon 1 and p = 0.25 for Amplicon 2).
Our comparison of the number of HIV templates se-
quenced across two regions of pol from specimens with a
range of clinical viral loads demonstrates several pitfalls
with MPS that can lead to insensitive assays for minority
species of the HIV population. The Primer ID method in our
study produced significantly fewer unique sequences than
estimated by the clinical viral load, only <1% to 14% of the
input estimated by viral load, which overlaps with the range
FIG. 1. The distribution of the
number of sequence reads per unique
Primer Identification tags (IDs) is
shown for Subject 4’s Amplicon 1. The
reads shown cover the entire amplicon,
and passed criteria for PCR primer,
primer ID, and Multiplex Identifier
(MID). The distribution was similar for
Amplicon 2 from this subject, but other
subjects had an even larger proportion
of reads discarded due to a larger pro-
portion of 1 or 2 reads per ID. Input for
this specimen was 11,355 copies based
on Abbott RealTime HIV-1 assay.
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reported by others.23 Submission of too many viral tem-
plates in our study reduced the proportion of templates se-
quenced. Alternatively, submission of too few templates
would not allow for detection of minority variants. Fur-
thermore, the proportion of templates amplified from a
specific specimen varied and did not correlate directly with
clinical viral load. Factors that may diminish amplification
of templates include specimen integrity, length of amplicon,
properties of reverse transcriptases and DNA polymerases,
and primer binding to specific templates.
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FIG. 2. The yield of human immunode-
ficiency virus (HIV) sequences labeled with
unique Primer Identification tags (IDs) is
affected by input of viral templates and
number of sequence reads. (A) The number
of HIV templates sequenced after filtering
for PCR primer, primer ID, Multiplex
Identifier (MID), and sequence length rel-
ative to the input of HIV RNA as quantified
by clinical viral load assay. Trends are
compared for Amplicon 1‡ 3 reads and
Amplicon 2‡ 3 reads (all IDs meeting filter
and having ‡3 reads per ID). (B) The pro-
portion of input HIV RNA templates cap-
tured by using ‡3 reads as criteria for
inclusion in the final data set. (A, B) A
triangle is used to denote the average of
Subject 6’s read from plate-1 and plate-2,
while a square is used to denote Subject 6’s
results when reads from both plates were
combined. The dashed trend line corre-
sponds to Amplicon 1 while the solid trend
line corresponds to Amplicon 2.
Table 2. Effect of Doubling the Number of Sequence Reads on the Number
of HIV Final Sequence Variants for Subject #6
Amplicon 1a Amplicon 2a
Subject #
Reads pass
filterb
Unique primer
ID ‡3 readsc
Final sequence
variantsd
Reads pass
filterb
Unique primer
ID ‡3 readsc
Final sequence
variantsd
6 (plate-1) 6,063 450 223 8,826 1,184 95
6 (plate-2) 5,418 354 344 11,693 1,402 640
6 (combined) 11,481 1,393 906 20,519 1,773 386
aSubject 6’s amplicon was sequenced twice, in two pyrosequencing plates.
bThe number of sequence reads that passed the filter (PCR primer, primer ID, MID, covering the full amplicon).
cUnique Primer IDs with ‡3 reads.
dNumber of final sequence variants generated from combining identical HIV sequences.
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Sequence analysis ‘‘pipelines’’ aim to increase the accu-
racy of data, however, elimination of poor-quality data fur-
ther reduces the yield of sequences. The fraction of non-full-
length reads generated by 454-pyrosequencing increases with
amplicon length, as shown by our yield from Amplicon 1
compared to Amplicon 2 (Supplementary Table S1). In ad-
dition, to correct for misinsertion of bases during PCR, the
Primer ID method discards sequence reads with Primer IDs
not represented by three or more reads. By increasing the
number of sequence reads for a given sample, as accom-
plished by assaying two aliquots of Subject 6’s amplicon, the
unique Primer IDs with ‡3 reads increased in number.
Clearly, relatively few reads per template limited the pro-
portion of viral templates sequenced across several of the
specimens we assayed, and emphasizes the need to optimize
the multiplicity of reads per viral templates amplified. Ad-
ditionally, by increasing the reads per template for Subject 6,
a greater proportion of our final sequences appears to be true
variants due to better error correction.
Analysis of 454-pyrosequencing without use of Primer IDs
and processed using ICC was not found to yield significantly
different numbers of sequence variants for Amplicon 2, but
the two methods differed for Amplicon 1, with the ICC
method producing fewer final sequence variants for Amplicon 1
(Fig. 3). This difference might have occurred due to diverse
handling of errors inherent in 454-pyrosequencing. Analysis
by Primer ID combines sequences into a consensus by identity
of the 8-bp random sequences added at the time of reverse
transcription, whereas ICC groups identical sequences across
the length of HIV pol into one final sequence variant. In ICC, if
two sequences were not grouped together due to error (mis-
match, indel, carry forward) this would generate a larger
number of final sequence variants. Increasing the number of
reads per template should make more Primer IDs available for
analysis, which should increase the number of templates with
‡3 reads and reduce all the aforementioned types of error by
combining variants into one consensus sequence; this may
have occurred with Amplicon 2 of Subject 6 (Fig. 3) where
FIG. 3. Number of final sequence
variants analyzed after processing by
either Primer Identification (ID) (using
‡3 reads for each consensus sequence)
or Insertion-deletion (indel) and Carry
Forward Correction (ICC) pipelines
showing Amplicon 1 and Amplicon 2
separately. The Primer ID method
produced more final sequence variants
than the ICC method for Amplicon 1,
but not for Amplicon 2 ( p= 0.028 and
p= 0.25, respectively, using the Wil-
coxon sign rank test at 95% confidence
level), most likely because the shorter
length of the template amplified pro-
duced a greater number of Primer ID
reads for Amplicon 2, which allowed
for more unique IDs with ‡3 reads.
FIG. 4. The pairwise diversity of
human immunodeficiency virus (HIV)
pol calculated using sequences gener-
ated by the Primer Identification (ID)
and the Insertion-deletion (indel) and
Carry Forward Correction (ICC) pipe-
lines,with standard errors (bars are very
small). The diversity calculated for
each amplicon appears similar between
the two methods ( p= 0.173 for Am-
plicon 1 and p= 0.25 for Amplicon 2
using the Wilcoxon sign rank test at
95% confidence level).
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increasing the number of reads decreased the final sequence
variants. The addition of more sequences by combining the
pools for Subject 6 appears to have condensed some previously
unique consensus sequences into one final sequence variant,
which has improved error correction.
The increase in final sequence variants for Subject 6’s
Amplicon 1 demonstrates that with more reads more novel
sequences were available since fewer IDs were discarded due
to the requirement of three or more reads, thus more IDs with
greater than three reads than the sum of plates 1 and 2 are
included in the analysis. However, fewer Primer IDs had the
same consensus sequence, thus fewer were combined for the
final set of sequence variants because a sequence variant is
defined as a unique sequence, not a unique ID, resulting in
more final sequence variants than the original sum of plates 1
and 2. This could be because Amplicon 1 covers a naturally
more diverse region in Subject 6’s virus and by increasing
reads more unique viral variants were sequenced. Alter-
natively, the longer length of Amplicon 1 or increased ho-
mopolymers in Amplicon 1 (27 homopolymers) compared to
Amplicon 2 (18 homopolymers) could artificially inflate the
number of final sequence variants. In contrast, the ICC
method corrects indel and carry forward errors at the se-
quence level by nonsubstitution sequence clustering,15 and
subsequently applies a statistical model to identify ‘‘true’’
variants using a known sequencing error distribution. This
error correction allows ICC to group sequences into a final
consensus sequence, allowing a higher template to read ratio
for error correction. It is also possible that the ICC method
overcorrects, and in doing so produces fewer final sequence
variants. Despite these differences in analysis, the viral di-
versity by the two methods were similar, with no significant
differences or trends between the two methods (Fig. 4).
Importantly, ICC does not provide the number of viral
templates evaluated in the assay, which is provided by the
Primer ID method, and is critical for assessing minority
variants in a viral population. However, the quantification of
viral templates by the Primer ID method could be artificially
increased due to substitution errors in the 8-bp Primer ID.24,25
Additionally, as the use of only eight random base combi-
nations for the Primer ID generates 48 or 65,536 different IDs,
input of a large number of viral templates will increase the
probability that each unique 8-bp sequence labels more than
one template, which would underestimate the number of
templates evaluated.25,26
The reports that HIV minority variants appear clinically
relevant and lead to virologic failure of ART5,6, 8–11 emphasize
the importance of data representative of the true proportions of
variants in the viral population. Administration of ART that
inhibits all replication-competent variants in an individual can
reduce virologic failure and minimize the spread of HIV, es-
pecially the spread of virus that is already resistant to certain
medications. To provide the most efficacious ART for each
patient, accurate testing of their viral population appears cru-
cial. Adequate sampling of the viral population is implicit to
quantifying minority variants, as is designing primers likely to
amplify all variants. Our data show that the use of the clinical
viral load does not accurately determine amplifiable viral
templates, and that amplification varies across specimens, due
to amplicon length, enzyme fidelity, PCR conditions, pre-
sumed primer biases, and/or inhibitory factors in the speci-
men.13,14 Omission of PCR by direct sequencing of sheared
nucleic acids using the Illumina platform eliminates primer
biases, but adds cost, as this method generates comparably
more human to viral sequences. The Illumina platform offers a
lower frequency of indel errors, and the more recent genera-
tions of the assay have read lengths comparable to the 454-
pyrosequencing platform.
The sequencing of relatively few HIV templates compared
to the predicted input from clinical viral loads as well as the
variability of the number of templates sequenced by gene
region and individual’s specimen all substantiate the utility of
the Primer ID method or direct sequencing of sheared nucleic
acids to quantify the number of viral templates sequenced to
quantify minority variants. Further comparative studies are
required to determine the relative advantages and costs of
these two methods as well as other methods.
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